Evidence map›Paper›PMID 34229329›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2021

Brief Report: Acute Kidney Injury in People Living With HIV Hospitalized With Coronavirus Disease 2019: Clinical Characteristics and Outcomes.

Molly C Fisher, Melissa J Fazzari, David B Hanna, Viraj V Patel, Uriel R Felsen, Emad Alahiri, Arjun Byju, Matthew J Akiyama, Mindy S Ginsberg, Kathryn Anastos and 1 more

Open access · greenAbstract read
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.1field-weighted citation impact, top 58% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Molly C FisherDivision of Nephrology, Albert Einstein College of Medicine, Montefiore Health System Bronx, NY.
Melissa J FazzariDepartment of Epidemiology and Population Health, Albert Einstein College of Medicine, Montefiore Health System Bronx, NY.
David B HannaDepartment of Epidemiology and Population Health, Albert Einstein College of Medicine, Montefiore Health System Bronx, NY.
Viraj V PatelDivision of General Internal Medicine, Albert Einstein College of Medicine, Montefiore Health System Bronx, NY.
Uriel R FelsenDivision of Infectious Diseases, Albert Einstein College of Medicine, Montefiore Health System Bronx, NY.
Emad AlahiriDivision of Nephrology, Albert Einstein College of Medicine, Montefiore Health System Bronx, NY.
Arjun ByjuAlbert Einstein College of Medicine Bronx, NY; and.
Matthew J AkiyamaDivision of General Internal Medicine, Albert Einstein College of Medicine, Montefiore Health System Bronx, NY.
Mindy S GinsbergDepartment of Epidemiology and Population Health, Albert Einstein College of Medicine, Montefiore Health System Bronx, NY.
Kathryn AnastosDivision of General Internal Medicine, Albert Einstein College of Medicine, Montefiore Health System Bronx, NY.
Michael J RossDivision of Nephrology, Albert Einstein College of Medicine, Montefiore Health System Bronx, NY.
Albert Einstein College of Medicine · USMontefiore Health System · US

Funding

Patient and Population Health Outcomes Research SWGP30AI124414 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI Vilma Gabbay · 2017 to 2026
$28.3M
Leveraging community health workers to improve SARS-CoV-2 testing and mitigation among criminal justice-involved individuals accessing a corrections-focused community-based organizationR01MD016744 · NIMHD · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI Matthew Akiyama · 2021 to 2026
$3.5M
Leveraging HCV Phylogenetic Networks to Prevent HIV and Other Blood Borne Infections Among People Who Inject DrugsDP2DA053730 · NIDA · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI AKIYAMA, MATTHEW · 2021 to 2021
$2.5M
TestED!: Applying Implementation Science to improve an HIV testing strategy for Emergency DepartmentsK23MH106386 · NIMH · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI FELSEN, URIEL · 2015 to 2019
$920k
Advance Care Coordination and Enhanced Linkage and Retention Among Transitional Re-Entrants LivingR00DA043011 · NIDA · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI AKIYAMA, MATTHEW · 2020 to 2022
$747k
Prediction of heart failure in HIV-infected individualsK01HL137557 · NHLBI · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI HANNA, DAVID B. · 2017 to 2020
$711k
NHLBI NIH HHS K01 HL137557NIAID NIH HHS P30 AI124414NIDA NIH HHS DP2 DA053730NIDA NIH HHS R00 DA043011NIMHD NIH HHS R01 MD016744NIMH NIH HHS K23 MH106386
6 · The paper itself

Abstract

backgroundData on clinical characteristics and outcomes of people living with HIV (PLWH) hospitalized with coronavirus disease 2019 (COVID-19) who develop acute kidney injury (AKI) are limited.

settingLarge tertiary health care system in the Bronx, NY.

methodsWe performed a retrospective cohort study of 83 PLWH and 4151 patients without HIV hospitalized with COVID-19 from March 10, 2020, to May 11, 2020. We compared the clinical characteristics and outcomes associated with AKI by HIV serostatus and evaluated HIV-related factors for AKI among PLWH. AKI was defined and staged using Kidney Disease Improving Global Outcomes criteria.

resultsThe incidence of AKI in hospitalized patients with COVID-19 did not differ significantly by HIV serostatus (54.2% in PLWH vs 49.5% in patients without HIV, P = 0.6). Despite a higher incidence of stage 3 AKI (28.9% vs 17.1% P = 0.05) in PLWH compared with those without HIV, there was no significant difference in the need for renal replacement therapy (22.2% vs 13.4% P = 0.12), renal recovery (76.9% vs 82.5% P = 0.61), or dependence on renal replacement therapy (7.7% vs 3.8% P = 0.27). CD4 T-cell count, HIV-1 RNA viral suppression, and antiretroviral therapy use were not associated with AKI. AKI was associated with increased need for invasive ventilation and in-hospital death, but HIV was not an independent risk factor of in-hospital death after AKI [adjusted hazard ratio 1.01 (95% CI: 0.59 to 1.72), P = 0.98].

conclusionsHIV-related factors were not associated with increased risk of AKI in PLWH hospitalized with COVID-19. PLWH hospitalized with COVID-19 had more stage 3 AKI, but outcomes after AKI were similar to those without HIV.

Indexed as

Acute Kidney InjuryAgedAntirheumatic AgentsCOVID-19FemaleHIV InfectionsHospital MortalityHumansIncidenceMaleMiddle AgedRetrospective StudiesRisk FactorsSARS-CoV-2Antirheumatic Agents

Identifiers

PMID34229329
PMCPMC8629144
OpenAlexW3179481242

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.